However, a re-analysis of the aforementioned meta-analysis including 71 trials and eight different VEGFR-TKIs suggested that the previously observed effect was exaggerated since, according to the authors, such treatment was associated with a slight elevation in the risk of bleeding, hypertension, thrombocytopenia and arterial thrombotic damage [119]. The gene discussed is KDR; the disease is hypertensive disorder.